Your browser doesn't support javascript.
loading
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andrés; Moore, Richard G; Vulsteke, Christof; O'Cearbhaill, Roisin E; Malinowska, Izabela A; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R; Monk, Bradley J.
Afiliación
  • González-Martín A; Medical Oncology Department, Cancer Center Clínica Universidad de Navarra, Madrid, Program in Solid Tumours, CIMA, Pamplona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain.
  • Pothuri B; Gynecologic Oncology Group (GOG Foundation), NYU Langone, Health, Department of Obstetrics & Gynecology, Perlmutter Cancer Center, New York, NY, USA.
  • Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, Division of Gynaecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Graybill W; GOG, Gynecologic Oncology, Medical University of South Carolina, Charleston, SC, USA.
  • Lorusso D; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
  • McCormick CC; GOG, Legacy Medical Group Gynecologic Oncology, Portland, OR, USA.
  • Freyer G; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), HCL Cancer Institute Department of Medical Oncology, Lyon University, Lyon, France.
  • Backes F; Division of Gynecologic Oncology, Ohio State University, Columbus, OH, USA.
  • Heitz F; AGO Study Group and the Department for Gynaecology and Gynaecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, Germany.
  • Redondo A; GEICO, Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
  • Moore RG; Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics and Gynecology, University of Rochester, Rochester, NY, USA.
  • Vulsteke C; BGOG, Department of Medical Oncology and Hematology, AZ Maria Middelares, Gent, Belgium; Department of Molecular Imaging, Pathology, Radiotherapy & Oncology, Center for Oncological Research, Antwerp University, Antwerp, Belgium.
  • O'Cearbhaill RE; GOG, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Malinowska IA; GSK, Middlesex, UK.
  • Shtessel L; GSK, Middlesex, UK.
  • Compton N; GSK, Middlesex, UK.
  • Mirza MR; Department of Oncology, Rigshospitalet-Copenhagen University Hospital and Nordic Society of Gynaecological Oncology, Copenhagen, Denmark.
  • Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix Creighton University, Phoenix, AZ, USA.
Eur J Cancer ; 189: 112908, 2023 08.
Article en En | MEDLINE | ID: mdl-37263896
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article País de afiliación: España